Match!
  • References (14)
  • Citations (0)
Cite
References14
Newest
Published on Apr 4, 2019in Brain11.81
Seth Love54
Estimated H-index: 54
(UoB: University of Bristol),
James A. R. Nicoll57
Estimated H-index: 57
+ 6 AuthorsClive Holmes55
Estimated H-index: 55
Published on Mar 1, 2019in Annals of Neurology9.50
Francesco Panza57
Estimated H-index: 57
(University of Bari),
Madia Lozupone12
Estimated H-index: 12
(University of Bari)
+ 1 AuthorsBruno P. Imbimbo36
Estimated H-index: 36
Published on Nov 2, 2018in Frontiers in Neuroscience3.65
Petr Novak7
Estimated H-index: 7
,
Eva Kontsekova16
Estimated H-index: 16
+ 1 AuthorsMichal Novak15
Estimated H-index: 15
Published on Feb 1, 2018in Biological Psychiatry11.50
Christopher H. van Dyck45
Estimated H-index: 45
(Yale University)
Abstract The majority of putative disease-modifying treatments in development for Alzheimer’s disease are directed against the amyloid-β (Aβ) peptide. Among the anti-Aβ therapeutic approaches, the most extensively developed is immunotherapy—specifically, passive immunization through administration of exogenous monoclonal antibodies (mAbs). Although testing of mAbs has been fraught with failure and confusing results, the experience gained from these trials has provided important clues for better ...
Published on Jan 1, 2017in Alzheimers & Dementia14.42
Randall J. Bateman40
Estimated H-index: 40
(WashU: Washington University in St. Louis),
Tammie L.S. Benzinger43
Estimated H-index: 43
(WashU: Washington University in St. Louis)
+ 15 AuthorsEric McDade26
Estimated H-index: 26
(WashU: Washington University in St. Louis)
Abstract Introduction The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer's disease in autosomal dominant Alzheimer's disease (ADAD) families. With completion of enrollment of the first two drug arms, the DIAN-TU now plans to add new drugs to the platform, designated as the Next Generation (NexGen) prevention trial. Methods In collaboration with ADAD families, philanthropic org...
Published on Sep 1, 2016in Nature43.07
Jeff Sevigny4
Estimated H-index: 4
,
Ping Chiao5
Estimated H-index: 5
+ 25 AuthorsYan Ling3
Estimated H-index: 3
Aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ, reduces soluble and insoluble Aβ in the brain, an action accompanied by a dose-dependent slowing of clinical decline in treated patients.
Published on Jan 1, 2016in Neurotherapeutics5.55
Elvira Valera15
Estimated H-index: 15
(UC: University of California),
Brian Spencer40
Estimated H-index: 40
(UC: University of California),
Eliezer Masliah139
Estimated H-index: 139
(UC: University of California)
Disease-modifying alternatives are sorely needed for the treatment of neurodegenerative disorders, a group of diseases that afflict approximately 50 million Americans annually. Immunotherapy is one of the most developed approaches in this direction. Vaccination against amyloid-β, α-synuclein, or tau has been extensively explored, specially as the discovery that these proteins may propagate cell-to-cell and be accessible to antibodies when embedded into the plasma membrane or in the extracellular...
Published on Mar 19, 2014in Science Translational Medicine17.16
Reisa A. Sperling87
Estimated H-index: 87
(Harvard University),
Dorene M. Rentz43
Estimated H-index: 43
(Harvard University)
+ 4 AuthorsPaul S. Aisen82
Estimated H-index: 82
(UCSD: University of California, San Diego)
A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer’s disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.
Published on Sep 1, 2010in Acta Neuropathologica18.17
Delphine Boche24
Estimated H-index: 24
(University of Southampton),
Nathan Denham1
Estimated H-index: 1
(University of Southampton)
+ 1 AuthorsJames A. R. Nicoll57
Estimated H-index: 57
(University of Southampton)
The amyloid cascade hypothesis of Alzheimer’s disease (AD) is testable: it implies that interference with Aβ aggregation and plaque formation may be therapeutically useful. Aβ42 immunisation of amyloid precursor protein (APP) transgenic mice prevented plaque formation and caused removal of existing plaques. The first clinical studies of Aβ immunisation in AD patients (AN1792, Elan Pharmaceuticals) were halted when some patients suffered side effects. Since our confirmation that Aβ immunisation c...
Published on May 1, 2010in Brain11.81
Alberto Serrano-Pozo21
Estimated H-index: 21
(CSIC: Spanish National Research Council),
Christopher M. William12
Estimated H-index: 12
(Harvard University)
+ 9 AuthorsJohn H. Growdon80
Estimated H-index: 80
(Harvard University)
Anti-amyloid-β immunization leads to amyloid clearance in patients with Alzheimer’s disease, but the effect of vaccination on amyloid-β-induced neuronal pathology has not been quantitatively examined. The objectives of this study were to address the effects of anti-amyloid-β active immunization on neurite trajectories and the pathological hallmarks of Alzheimer’s disease in the human hippocampus. Hippocampal sections from five patients with Alzheimer’s disease enrolled in the AN1792 Phase 2a tri...
Cited By0
Newest